Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Licensed medicineStub

Dulaglutide

GLP-1 receptor agonist

A once-weekly GLP-1 receptor agonist, licensed for type 2 diabetes. Trials of newer agonists often use it as the active comparator.

Reconstitution calculator

At a glance

Licensed medicine

A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine: Dulaglutide

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

540
papers on PubMed
334
of them in people
115
randomized trials
42
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Dulaglutide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Dulaglutide; no amount here is a recommendation.

Dulaglutide: on PubMed

What PubMed held for Dulaglutide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

540
papers
334
in humans
125
clinical trials
115
randomized trials
2012: 4 papers122013: 0 papers2014: 13 papers142015: 28 papers2016: 31 papers162017: 22 papers2018: 41 papers182019: 52 papers2020: 50 papers202021: 49 papers2022: 54 papers222023: 64 papers2024: 65 papers242025: 70 papers2026: 59 papers so far26
Papers per year, 2012 to 2026. The most in one year: 70.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

    Randomized trialGerstein HC, Colhoun HM, Dagenais GR, et al. Lancet (London, England), 2019. PMID 31189511

  2. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

    TrialNicholls SJ, Pavo I, Bhatt DL, et al. The New England journal of medicine, 2025. PMID 41406444

  3. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

    Randomized trialPratley RE, Aroda VR, Lingvay I, et al. The lancet. Diabetes & endocrinology, 2018. PMID 29397376

  4. Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis

    ReviewKarimi MA, Gholami Chahkand MS, Dadkhah PA, et al. Frontiers in pharmacology, 2025. PMID 40444045

  5. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial

    Randomized trialNissen SE, Wolski K, D'Alessio D, et al. JAMA cardiology, 2026. PMID 41903177

  6. Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials

    Meta-analysisAyesh H, Ayesh S, Niswender K American journal of therapeutics, 2024. PMID 38976545

  7. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics

    TrialNicholls SJ, Bhatt DL, Buse JB, et al. American heart journal, 2024. PMID 37758044

  8. Dulaglutide

    Review, 2006. PMID 30000038

Search used: ("Dulaglutide"[ti]). Run it on PubMed

Research links

Also in Metabolic